mirage

Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use

Repositorio ABACUS/Manakin

Mostrar el registro sencillo del ítem

dc.contributor.author Ampudia-Blasco, Francisco Javier
dc.contributor.author Calvo Gómez, Carlos
dc.contributor.author Cos Claramunt, Xavier
dc.contributor.author García Alegría, Javier
dc.contributor.author Jódar Gimeno, Esteban
dc.contributor.author Mediavilla Bravo, José Javier
dc.contributor.author Mezquita Raya, Pedro
dc.contributor.author Navarro Pérez, Jorge
dc.contributor.author Puig Domingo, Manuel
dc.date.accessioned 2016-06-30T14:56:48Z
dc.date.available 2016-06-30T14:56:48Z
dc.date.issued 2010
dc.identifier.citation Ampudia-Blasco, F. J., Calvo Gómez, C., Cos Claramunt, X., García Alegría, J., Jódar Gimeno, E., Mediavilla Bravo, J., ... & Puig Domingo, M. (2010). Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use. Expert Review of Endocrinology & Metabolism, 5(6), 799-807. spa
dc.identifier.issn 17446651
dc.identifier.issn 17448417
dc.identifier.uri http://hdl.handle.net/11268/5350
dc.description.abstract Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinical practice. It has recently been approved by the EMA and the US FDA for treatment of Type 2 diabetes mellitus (T2DM). Initial approval is for use in combination with either metformin or a sulfonylurea, or in combination with metformin plus a sulfonylurea or thiazolidinedione. Liraglutide monotherapy is approved in the USA. Results from the Liraglutide Effect and Action in Diabetes (LEAD) clinical trials program indicate that liraglutide significantly lowers glycosylated hemoglobin (HbA1c) with a low risk of hypoglycemia. Liraglutide is also associated with significant and sustained weight loss, decreased systolic blood pressure, and improvements in other markers of cardiovascular risk. Liraglutide also shows strong potential to preserve β-cell function. Maximum benefits may be achieved when liraglutide treatment is initiated early on in the course of T2DM. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.subject.other Diabetes tipo 2 spa
dc.title Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use spa
dc.type article spa
dc.description.impact 0.213 SJR (2010) Q3, 114/183 Endocrinology, diabetes and metabolism spa
dc.rights.accessRights closedAccess spa
dc.subject.uem Diabetes spa
dc.subject.unesco Enfermedad cardiovascular spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem